iPrEx
Trial: Chemoprophylaxis for HIV Prevention in Men
Rationale: Pre-exposure prophylaxis is a strategy that aims to use antiretrovirals to reduce the risk of HIV infection. Studies in non-human primates have shown that both oral and topical applications of ARVs before exposure reduce risk or completely prevent infection with challenge by an HIV-like virus that causes disease in monkeys.
TDF/FTC (marketed under the name Truvada) is an antiretroviral used by HIV-positive people as part of highly active antiretroviral therapy.
Study question(s): This study is to evaluate the safety and effectiveness of daily TDF/FTC in preventing HIV transmission in HIV-negative men who have sex with men.
Participants: 2,499 HIV-negative gay men and other men who have sex with men
Countries: Brazil, Ecuador, Peru, South Africa, Thailand, US
Trial sponsors and collaborators: Bill & Melinda Gates Foundation, Gilead Sciences, US National Institutes of Health (NIH)
When can we expect results? Results announced November 23, 2010. Visit www.avac.org/iprex for details.
To learn more visit:
http://clinicaltrials.gov/ct2/show/NCT00458393?term=Chemoprophylaxis+for+HIV+Prevention+in+Men&rank=1
http://www.globaliprex.net/StudyDesign.html
| Complete | Yes |